Clinical Trial

Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma

Name: Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma — clinical trial record (NCT07187960)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

Evaluation of the efficacy and safety of TQB2825 injection compared to immunotherapy in the treatment of recurrent/refractory follicular lymphoma.

Trial Details

NCT Number	NCT07187960
Lead Sponsor	Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Conditions	Follicular Lymphoma
Enrollment	228 participants
Start Date	2025-11
Primary Completion	2028-10 (estimated)
Study Completion	2029-02 (estimated)
Updated on ClinicalTrials.gov	2025-09-23